TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

1 Undervalued Growth Stock Down 8% to Buy Before 2026

The Motley Fool Logo The Motley Fool By Prosper Junior Bakiny
1 Undervalued Growth Stock Down 8% to Buy Before 2026

Eli Lilly, a pharmaceutical company, is experiencing a temporary stock pullback but remains a strong investment due to its exceptional growth potential, particularly in weight management medicines like tirzepatide and the upcoming oral GLP-1 medicine orforglipron.

Insights
LLY   positive

Strong revenue growth, breakthrough weight management drugs (tirzepatide), potential to become top pharmaceutical company by 2030, consistent dividend increases, and promising future product pipeline